Researchers have discovered that a long non-coding RNA called NORAD plays a crucial role in the development of coronary artery disease (CAD). By analyzing blood samples from CAD patients and healthy individuals, the study found that elevated levels of NORAD are a potential biomarker for identifying CAD. The findings also reveal how NORAD regulates endothelial cell function, impacting cell proliferation, migration, and a process called ferroptosis that can contribute to the progression of atherosclerosis. This study sheds light on the complex interplay between non-coding RNAs and cardiovascular health, opening up new avenues for early detection and targeted therapeutic interventions.
Elevated NORAD Levels Linked to Coronary Artery Disease
Atherosclerosis, the buildup of plaque in the arteries, is a leading cause of cardiovascular disease. This can lead to serious conditions like heart attacks and strokes, posing a significant public health challenge. Understanding the underlying mechanisms driving atherosclerosis is crucial for developing better diagnostic tools and treatments.
In this study, researchers examined the role of a long non-coding RNA called NORAD in the development of CAD. Long non-coding RNAs (lncRNAs) are RNA molecules that do not encode proteins but play important regulatory roles in various cellular processes. The researchers recruited 75 CAD patients and 76 healthy controls and measured the levels of NORAD in their blood plasma.
The results revealed that NORAD levels were significantly elevated in CAD patients compared to the control group. Further analysis showed that NORAD had a high accuracy in distinguishing CAD patients from healthy individuals, suggesting its potential as a novel biomarker for early detection of the disease.
NORAD Regulates Endothelial Cell Function
Endothelial cells line the inner surface of blood vessels and play a crucial role in maintaining vascular health. Dysfunction or damage to these cells can contribute to the development of atherosclerosis. The researchers investigated how NORAD influences the behavior of endothelial cells.
By silencing the expression of NORAD in human umbilical vein endothelial cells (HUVECs), the team found that it led to:
– Inhibition of cell migration and proliferation: NORAD knockdown caused a decrease in the expression of cell cycle-related genes, such as CCND1, leading to a halt in the cell cycle at the G0/G1 phase.
– Induction of early apoptosis: NORAD silencing increased the proportion of early apoptotic cells, suggesting it may play a role in regulating programmed cell death.
These findings indicate that NORAD is crucial for maintaining the proper function of endothelial cells, and its dysregulation could contribute to the development of atherosclerosis.
NORAD Modulates Ferroptosis, a Specialized Form of Cell Death
The study also explored the connection between NORAD and ferroptosis, a type of regulated cell death that is characterized by the accumulation of iron-dependent lipid peroxides. Ferroptosis has been implicated in the pathogenesis of various diseases, including cardiovascular disorders.
When the researchers silenced NORAD in endothelial cells, they observed several hallmarks of ferroptosis:
– Increased reactive oxygen species (ROS) levels: NORAD knockdown led to a significant rise in intracellular ROS, which can drive lipid peroxidation and cell death.
– Decreased antioxidant defenses: The expression of key ferroptosis-regulating proteins, such as GPX4 and FTH1, was reduced in NORAD-silenced cells, compromising the cells’ ability to protect against oxidative stress.
– Mitochondrial dysfunction: NORAD silencing impaired the mitochondrial membrane potential, which is a characteristic feature of ferroptosis.
These findings suggest that NORAD may play a protective role against ferroptosis in endothelial cells, and its downregulation could contribute to the progression of atherosclerosis by promoting this specialized form of cell death.
Unraveling the Regulatory Network of NORAD
To further understand the mechanisms by which NORAD exerts its effects, the researchers constructed a competing endogenous RNA (ceRNA) network. This network revealed that NORAD interacts with and regulates the expression of the microRNA miR-106a, which in turn targets the cell cycle regulator CCND1.
The study demonstrated that NORAD acts as a sponge for miR-106a, sequestering it and preventing it from binding to and suppressing CCND1. By maintaining higher levels of CCND1, NORAD promotes endothelial cell proliferation and migration, and also protects against ferroptosis-induced cell death.
Implications and Future Directions
This study provides valuable insights into the role of long non-coding RNAs in the development and progression of coronary artery disease. The findings suggest that NORAD could serve as a promising biomarker for the early detection of CAD, as well as a potential therapeutic target for interventions aimed at preserving endothelial cell function and mitigating the impact of ferroptosis-driven cell death.
Further research is needed to fully elucidate the complex interplay between NORAD, miRNAs, and other regulatory networks in the context of cardiovascular health. Additionally, investigating the therapeutic potential of modulating NORAD expression or activity could lead to the development of novel strategies for the prevention and treatment of atherosclerosis and related cardiovascular disorders.
Author credit: This article is based on research by Tao He, Junxing Pu, Haijing Ge, Tianli Liu, Xintong Lv, Yu Zhang, Jia Cao, Hong Yu, Zhibing Lu, Fen Du.
For More Related Articles Click Here
